Advertisement

The Use of Polyvalent Immunoglobulin G in Patients with Sepsis and Multiple Organ Failure

  • G. Pilz
  • K. Werdan

Abstract

Among critically ill patients admitted to intensive care units, septic multiple organ failure (MOF) and shock are major causes of death, with fatality rates in the case of septic shock in the range of 40%–90% [24]. This unvaryingly high sepsis mortality, despite advances in antibiotic treatment, provides the rationale for the investigation of supplementary sepsis treatment regimens as an attempt to improve the poor outcome of septic patients.

Keywords

Septic Shock Septic Patient Systemic Vascular Resistance Multiple Organ Failure Left Ventricular Stroke Work Index 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Baumgartner JD (1990) Arguments for the administration of immunoglobulins in critically-ill patients. In: Peter K, Lawin P, Bein T, Briegel J (eds) Intensivmedizin, vol 76. Thieme, Stuttgart, pp 152–157Google Scholar
  2. 2.
    Baumgartner JD (1991) Prophylactic study of standard intravenous Immunoglobulin and core LPS immunoglobulin in high-risk post surgical patients. Abstract SY 81 2nd International congress on the immune consequences of trauma, shock and sepsis—mechanisms and therapeutic approaches, Munich, 6–9 March. Demeter Gräfelfing, p 26Google Scholar
  3. 3.
    Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA, and the Methylprednisolone Severe Sepsis Study Group (1989) Sepsis syndrome: a valid clinical entity. Crit Care Med 17:389–393PubMedCrossRefGoogle Scholar
  4. 4.
    Class I, Schorer R (1989) Adjuvant therapy with Pseudomonas hyperimmune globulin. Anasth Intensivther Notfallmed 24:167–171PubMedCrossRefGoogle Scholar
  5. 5.
    Collins MS, Roby RE (1984) Protective activity of an intravenous immune globulin (human) enriched in antibody against lipopolysaccharide antigens of Pseudomonas aeruginosa. Am J Med 76, Suppl 3A:168–174PubMedCrossRefGoogle Scholar
  6. 6.
    Collins MS, Hector RF, Roby RE, Edwards AA, Ladehoff DK, Dorsey JH (1987) Prophylaxis of Gram-negative and Gram-positive infections in rodents with three intravenous immunoglobulins and therapy of experimental polymicrobial burn wound sepsis with Pseudomonas immunoglobulin and Ciprofloxacin. Infection 15:60–68PubMedCrossRefGoogle Scholar
  7. 7.
    Dalhoff A (1984) Synergy between acylureidopenicillins and immunoglobulin G in experimental animals. Am J Med 76:91–100PubMedCrossRefGoogle Scholar
  8. 8.
    Dalhoff A (1985) In vitro and in vivo effect of immunoglobulin G on the integrity of bacterial membranes. Infection 13, Suppl 2:S185–191PubMedCrossRefGoogle Scholar
  9. 9.
    De Simone C, Delogu G, Corbetta G (1988) Intravenous immunoglobulins in association with antibiotics: a therapeutic trial in septic intensive care unit patients. Crit Care Med 16:23–26PubMedCrossRefGoogle Scholar
  10. 10.
    Dickgießer N, Kustermann B (1986) IgG antibodies against toxic shock syndrome toxin-1 (TSST-1) in human immunoglobulins. Klin Wochenschr 64:633–635PubMedCrossRefGoogle Scholar
  11. 11.
    Dominioni L, Dionigi R, Zanello M, Chiaranda, M, Dionigi R, Acquarolo A, Ballabio A, Sguotti C (1991) Effects of high-dose IgG on survival of surgical patients with sepsis scores of 20 or greater. Arch Surg 126:236–240PubMedCrossRefGoogle Scholar
  12. 12.
    Duswald KH, Müller K, Seifert J, Ring J (1980) Wirksamkeit von i.v. Gammaglobulin gegen bakterielle Infektionen chirurgischer Patienten—Ergebnisse einer kontrollierten, randomisierten klinischen Studie. Münch Med Wochenschr 122:832–836Google Scholar
  13. 13.
    Elebute EA, Stoner HB (1983) The grading of sepsis. Br J Surg 70:29–31PubMedCrossRefGoogle Scholar
  14. 14.
    Glinz W, Grob, PJ, Nydegger UE, Ricklin T, Stamm F, Stoffel D, Lasance A (1985) Polyvalent immunoglobulins for prophylaxis of bacterial infections in patients following multiple trauma— a randomized, placebo-controlled study. Intensive Care Med 11:288–294PubMedCrossRefGoogle Scholar
  15. 15.
    Grundmann R, Kipping N, Wesoly C (1988) Der “Sepsisscore” von Elebute und Stoner zur Definition der postoperativen Sepsis auf der Intensivastation. Intensiv Med 25:268–273Google Scholar
  16. 16.
    Hill HR, Bathras JM (1986) Protective and opsonic activities of a native, pH 4.25 intravenous immunoglobulin G preparation against common bacterial pathogens. Rev Infect Dis 8, Suppl 4:S396–S400PubMedCrossRefGoogle Scholar
  17. 17.
    Jesdinsky HJ, Tempel G, Castrup HJ, Seifert J (1987) Cooperative group of additional immunoglobulin therapy in severe bacterial infections: results of a multicenter randomized controlled trial in cases of diffuse fibrinopurulent peritonitis. Klin Wochenschr 65:1132–1138PubMedCrossRefGoogle Scholar
  18. 18.
    Just HM, Metzger M, Vogel W, Pelka RB (1986) Therapeutic effects of immunoglobulin in intensive care patients with severe infections. Klin Wochenschr 64:245–256PubMedCrossRefGoogle Scholar
  19. 19.
    Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) APACHE II: A severity of disease classification system. Crit Care Med 13:818–829PubMedCrossRefGoogle Scholar
  20. 20.
    Lehmkuhl P, Pichlmayr I (1991) Sepsis-Therapie mit 5-S-Immunglobulinen. In: Deutsch E, Gadner H, Graninger W, Kleinberger G, Lenz K, Ritz R, Schuster HP, Zaunschirm HA (eds) Infecktionen auf Intensivstationen. Springer, Vienna New York, pp 127–137 (Inensivmedizinisches Seminar, vol. 3)CrossRefGoogle Scholar
  21. 21.
    Machin D, Campbell MJ (1987) Statistical tables for the design of clinical trials. Blackwell, OxfordGoogle Scholar
  22. 22.
    Mao P, Enrichens F, Olivero G, Festa T, Benedetto G, Sciascia C, Visetti E, Mauri A, Olivero S (1989) Early administration of intravenous immunoglobulins in the prevention of surgical and post-traumatic sepsis: a double blind randomized clinical trial. Surg Res Comm 5:93–98Google Scholar
  23. 23.
    Müller U, Werdan K (1990) Pseudomonas exotoxin A inhibits protein biosynthesis in neonatal rat heart muscle cells and modifies the inotropic state of these cells. J Mol Cell Cardiol 22: Suppl 3:26CrossRefGoogle Scholar
  24. 24.
    Parker MM, Parrillo JE (1983) Septic shock: hemodynamics and pathogenesis. JAMA 250:3324–3327PubMedCrossRefGoogle Scholar
  25. 25.
    Pennington JE, Pier GB (1987) Pseudomonas aeruginosa immunoglobulin in experimental pneumonia. Infection 15, Suppl 2:S47–S49PubMedCrossRefGoogle Scholar
  26. 26.
    Pilz G, Werdan K (1990) Cardiovascular parameters and scoring systems in the evaluation of response to therapy in sepsis and septic shock. Infection 18:253–262PubMedCrossRefGoogle Scholar
  27. 27.
    Pilz G, Kääb S, Neeser G, Class I, Schweigart U, Brähler A, Bujdoso O, Neumann R, Werdan K (1991) Supplemental immunoglobulin (ivIgG) treatment in 163 patients with sepsis and septic shock—an observational study as a prerequisite for placebo-controlled clinical trials. Infection 19:216–227PubMedCrossRefGoogle Scholar
  28. 28.
    Pilz G, Class I, Boekstegers P, Pfeifer A, Müller U, Werdan K (1991) Pseudomonas immunoglobulin therapy in patients with Pseudomonas sepsis and septic shock. Antibiot Chemother 44:120–135PubMedGoogle Scholar
  29. 29.
    Pilz G, Gurniak T, Bujdoso O, Werdan K (1991) A BASIC program for calculation of APACHE II and Elebute scores and sepsis evaluation in intensive care medicine. Comput Biol Med 21:143–159PubMedCrossRefGoogle Scholar
  30. 30.
    Pollack M (1983) Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans. J Infect Dis 147:1090–1098PubMedCrossRefGoogle Scholar
  31. 31.
    Schedel I (1988) Ein IgM angereichertes Immunglobulinpräparat in der Behandlung von Sepsis und septischem Schock—eine knotrollierte randomisierte Studie. In: Deicher H, Schoeppe W (eds) Klinisch angewandte Immunologie—Sepsistherapie mit IgM-angereichertem Immunglobulin. Springer, Berlin Heidelberg New York pp 16–29Google Scholar
  32. 32.
    Stuttmann R, Hartert M, Coleman JE, Kill H, Germann G, Doehn M Prophylactic administration of Pseudomonas immunoglobulin to burn patients. Intensiv Med 26 [Suppl. 1]: 130–137Google Scholar
  33. 33.
    Vogel F (1988) Bewertung der intravenösen IgM-Therapie bei schweren nosokomialen Infektionen (Ergebnis einer kontrollierten randomisierten Studie). In: Deicher H, Schoeppe W (eds) Klinisch angewandte Immunologie—Sepsistherapie mit IgM-angereichertem Immunglobulin. Springer, Berlin Heidelberg New York pp 30–41Google Scholar
  34. 34.
    Werdan K, Melnitzki SM, Pilz G, Kapsner T (1989) The cultured rat heart cell: a model to study direct cardiotoxic effects of Pseudomonas endo- and exotoxins. In: Schlag G, Redl H (eds) Progress in clinical and biological research 2nd Vienna Shock Forum, vol 308. Liss, New York, pp. 247–251Google Scholar
  35. 35.
    Yap PL (1987) The use of intravenous immunoglobulin for the treatment of infection: an overview. J Infect 15, Suppl 1:21–28PubMedCrossRefGoogle Scholar
  36. 36.
    Ziegler EJ, Fisher CJ, Sprung CL, Straube RC, Sadoff JC, Forlke GE, Wortel CH, Fink MP, Dellinger RP, Teng NNH, Allen IE, Berger HJ, Knatterud GL, LoBuglio AF, Smith CR, and the HA-1A, Sepsis Study Group (1991) Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin—a randomized, double-blind, placebo-controlled trial. N Engl J Med 324:429–436PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag, Berlin Heidelberg 1993

Authors and Affiliations

  • G. Pilz
    • 1
  • K. Werdan
    • 1
  1. 1.Department of Medicine I, Grosshadern University HospitalUniversity of MunichMunich 70Germany

Personalised recommendations